A joint model for nonlinear longitudinal data with informative dropout.
about
Modeling disease progression in acute stroke using clinical assessment scales.Pharmacodynamic models for discrete data.Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.Missing data in model-based pharmacometric applications: points to consider.Tips and traps analyzing pediatric PK data.Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.Matched longitudinal analysis of biomarkers associated with survivalTracking motor impairments in the progression of Huntington's disease.Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD)Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.Joint modeling of multiple longitudinal patient-reported outcomes and survivalModeling and simulation of adherence: approaches and applications in therapeutics.Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.A time to event tutorial for pharmacometricians.Establishing the Quantitative Relationship Between Lanreotide AutogelĀ®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.Review: efficient rehabilitation trial designs using disease progress modeling: a pediatric traumatic brain injury example.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Modelling and simulation of placebo effect: application to drug development in schizophrenia.Model-based clinical drug development in the past, present and future: a commentary.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals.Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancerNonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsEstablishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Extensions to the visual predictive check to facilitate model performance evaluation.Performance of nonlinear mixed effects models in the presence of informative dropout.Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression.Development of a placebo effect model combined with a dropout model for bipolar disorder.Continuous-time Markov modelling of flexible-dose depression trials.Postoperative analgesia using diclofenac and acetaminophen in children.Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.Interpreting the results of Parkinson's disease clinical trials: time for a change.Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint.Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
P2860
Q30497328-FBE52F8D-C69D-4185-ACB9-D8D883ACCCF0Q30578472-55166559-695A-4909-82FE-43E8BF418E38Q30770186-308FA132-9EC8-4C77-B118-C304ABECD36AQ30813682-EA7A8C6B-9018-4A58-BAC3-F6C596DF42C9Q33706156-4BF867D3-E57A-4421-A8C3-7038C1D89296Q33820152-E42DDE4C-FF60-4960-BEA3-2382D65FE6CFQ33822458-CB6EF438-E5A7-4EE5-980E-2924705FC213Q34057689-164BAD58-2141-4149-8917-93A562007BA9Q34449476-58506A7B-8CC2-4505-BAEA-9323EB88126BQ34990277-439CCB18-814E-4417-BD5B-6DA74CB08349Q34996927-581516D4-4F55-4035-A208-C782D7DDF867Q35540770-14C02621-33C7-4302-89D7-028A9BA0F7BBQ36341606-96D59905-39BC-4B41-9F37-E63C8B104382Q36407822-6E5B9B39-8020-4088-B219-74FD74F614FFQ36907009-1377F302-AA0E-4213-8021-64F4DC6F743BQ37600371-7F9DE577-71B3-4F9A-B1A2-DC98326692F5Q37644175-8B433123-5895-41C0-9F64-4026354C3BD0Q37886138-A10FCED8-942F-4AAD-BDBD-3A0AFCF28A3BQ38073697-3A86B0C3-2526-47C8-A7A6-A8DF44461728Q38188035-28C3889B-3890-4508-97A8-80913295BC1DQ38289581-C65F5765-F256-456C-8079-A338D25DB2CDQ39064765-228708A2-23A7-4BBD-BCD1-6AD727AFAF9BQ39739357-7103F6A2-706A-485C-812C-B27901272674Q39803248-3311ABFE-5C26-4862-9C6B-62712F388F56Q39885760-16F31538-809D-448B-8742-A5D4A5E4A107Q39959170-BF12F908-1DFB-4977-BE89-9412E666B1F6Q41775229-2B809158-B9C5-4B60-B725-311E1501BB4EQ41819996-A01A95AE-3B57-4D95-A754-25BA042CF511Q42947696-85FF3069-A6D4-4173-B3F4-A01188B790F9Q43096322-2580B4FA-CDC1-427F-86A5-91A0CAA4827BQ43199874-A78F1517-0A5E-4282-8B94-9178BDABFCEFQ43457571-8A14E3CF-5604-4628-99CB-AA51BA434835Q43480141-88089363-2470-4745-BD48-E5662A59B74EQ43940338-EB7B1CA9-3E00-4E23-849C-BC623EFE084EQ44066008-C2115276-EC71-4AE8-925F-00A067A9D532Q44201303-C28F414C-AA2F-413E-982F-DB80DD59F9ADQ44271163-6E65EA71-D8D4-47D8-9127-0EB450327F38Q45797972-3031806C-E539-4731-9AD8-8E71B3445354Q46353544-76560EE7-D662-4E39-B9B9-1E8218B5ED59Q48017570-71C6D7FC-B84E-47BE-BCAF-973484E54967
P2860
A joint model for nonlinear longitudinal data with informative dropout.
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2003 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2003幓ć®č«ę
@ja
2003幓č«ę
@yue
2003幓č«ę
@zh-hant
2003幓č«ę
@zh-hk
2003幓č«ę
@zh-mo
2003幓č«ę
@zh-tw
2003幓č®ŗę
@wuu
name
A joint model for nonlinear longitudinal data with informative dropout.
@ast
A joint model for nonlinear longitudinal data with informative dropout.
@en
type
label
A joint model for nonlinear longitudinal data with informative dropout.
@ast
A joint model for nonlinear longitudinal data with informative dropout.
@en
prefLabel
A joint model for nonlinear longitudinal data with informative dropout.
@ast
A joint model for nonlinear longitudinal data with informative dropout.
@en
P356
P1476
A joint model for nonlinear longitudinal data with informative dropout.
@en
P2093
Chuanpu Hu
Mark E Sale
P2888
P304
P356
10.1023/A:1023249510224
P577
2003-02-01T00:00:00Z
P6179
1019286936